No Benefit of Antiplatelets in Noncritical COVID: ACTIV-4a No Benefit of Antiplatelets in Noncritical COVID: ACTIV-4a

The P2Y12 inhibitor drugs ticagrelor or clopidogrel did not increase survival or time without organ support in noncritically ill, hospitalized patients with COVID-19 in the ACTIV-4a trial.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Cardiology News Source Type: news